US FDA Eager To INTERACT With Start-Ups, Not Check Boxes

A US FDA webinar for start-up sponsors showcased staff who sound enthusiastic about helping drug developers advance their projects, while also emphasizing the importance of early and continual engagement with the agency.

meeting
The FDA wants start-ups to take advantage of all meeting opportunities. • Source: Shutterstock

The new INTERACT meeting process can be a critical step for start-up sponsors to avoid early stumbles in their attempts to move into human trials, US Food and Drug Administration officials emphasized during a recent webinar offering “Regulatory Do’s and Don’ts” for small businesses.

Key Takeaways
  • FDA officials want start-up sponsors to take advantage of opportunities to meet with the agency.

“I highly recommend you take advantage of the meeting opportunities” outlined during the webinar, Center for Biologics Evaluation and Research...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Pink Sheet

EMA Poised To Decide On Fate Of Lilly’s Kisunla And PharmaMar’s Aplidin In EU

 
• By 

Eli Lilly and PharmaMar were set to make their case before the European Medicines Agency this week as part of re-examination procedures for their respective drugs Kisunla and Aplidin.

Complete Response Letter Trio Raises Prospect Of Tidal Shift In Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

After Sarepta Reversed Course On Elevidys, Could An Adcomm Be Next?

 

One option for the FDA going forward could be holding an advisory committee meeting on its safety concerns after Sarepta agreed to stop all shipments of its DMD gene therapy.